CMap analysis identified tivozanib, a selective VEGFR-1/-2/-3 inhibitor with established antiangiogenic efficacy in renal cell carcinoma,67 as the top candidate for reversing pathological gene signatures in high-risk HCC. This evidence concerns the gene FLT1 and renal cell carcinoma.